Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
ATMARINOMED6
Fri, 11.10.2024
Marinomed Biotech AG
Korneuburg, Austria, 11. October 2024 - Marinomed Biotech AG (the "Company") announces that, after a thorough review of existing offers, the Management Board today decided to enter contract negotiations for the sale of the Carragelose portfolio in the form of an asset deal. The Company selected the potential buyer based on a combination of favorabl [ … ]
Tue, 08.10.2024
Marinomed Biotech AG
Marinomed Biotech AG publishes remarkable results showing alleviation of allergic eye inflammation in patients treated with Tacrolimus eye drops in peer-reviewed journal
Tacrosolv eye drops, a low-dose, aqueous Marinosolv-enabled formulation of Tacrolimus, are safe and effective in alleviating symptoms of allergic rhinoconjunctivitis
Data from ph [ … ]
Tue, 24.09.2024
Marinomed Biotech AG
Marinomed Biotech AG reports positive clinical results for unique Carragelose eye drops
Marinomeds new Carragelose eye drops improve dry eye-related symptoms in patients with mild to moderate dry eye syndrome by remarkable 54%
Product was well tolerated by patients and ocular surface disease index (OSDI) was significantly reduced
Eye drops hold [ … ]
Tue, 24.09.2024
Marinomed Biotech AG
Marinomed Biotech AG reports positive clinical results for unique Carragelose eye drops
Marinomeds new Carragelose eye drops improve dry eye-related symptoms in patients with mild to moderate dry eye syndrome by remarkable 54%
Product was well tolerated by patients and ocular surface disease index (OSDI) was significantly reduced
Eye drops hold [ … ]
Wed, 18.09.2024
Marinomed Biotech AG
Korneuburg, Austria, 18. September 2024 - Marinomed Biotech AG (the “Company”) announces that the Management Board has resolved today to increase the Company's share capital by EUR 154,053 to EUR 1,694,583 by issuing 154,053 new no-par value bearer shares against cash contributions. The new shares will be issued from the authorized capital 2024 and [ … ]
Wed, 18.09.2024
Marinomed Biotech AG
Korneuburg, Austria, 18. September 2024 - Marinomed Biotech AG (the “Company”) announces that the Management Board has resolved today to increase the Company's share capital by EUR 154,053 to EUR 1,694,583 by issuing 154,053 new no-par value bearer shares against cash contributions. The new shares will be issued from the authorized capital 2024 and [ … ]
Sun, 15.09.2024
Marinomed Biotech AG
Korneuburg, Austria, 15. September 2024 – Marinomed Biotech AG (the “Company”) announces that today the Management Board decided to set a price range of EUR 4.90 to a maximum of EUR 5.20 per new share for a potential capital increase of up to 154,053 new shares to be issued under the Authorized Capital 2024 and subject to the direct exclusion of th [ … ]
Sun, 15.09.2024
Marinomed Biotech AG
Korneuburg, Austria, 15. September 2024 – Marinomed Biotech AG (the “Company”) announces that today the Management Board decided to set a price range of EUR 4.90 to a maximum of EUR 5.20 per new share for a potential capital increase of up to 154,053 new shares to be issued under the Authorized Capital 2024 and subject to the direct exclusion of th [ … ]
Wed, 11.09.2024
Marinomed Biotech AG
Marinomed Biotech AG: First Carragelose products receive new Medical Device Regulation (MDR) certification
Two Carragelose nasal sprays have received declaration of conformity under the new medical device regulation - certificates for further products expected later in the year
Extensive clinical data for Carragelose facilitates challenging deman [ … ]
Mon, 02.09.2024
Marinomed Biotech AG
Korneuburg, Austria, 02. September 2024 - Marinomed Biotech AG (the “Company”) announces that the Management Board decided today to evaluate a capital increase of up to 154,053 new shares to be issued from the Authorized Capital 2024, subject to the direct exclusion of statutory subscription rights of existing shareholders, to finance the ongoing c [ … ]